Drug Database
TE

teriparatide (SBL001 / Kauliv / SBL 001)

✓ Approved

Stelis Biopharma · PTH1R

What is teriparatide?

teriparatide is a therapeutic agent developed by Stelis Biopharma. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesSBL001, Kauliv, SBL 001
CompanyStelis Biopharma
Molecular TargetPTH1R
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Stelis Biopharma

Mechanism of Action

Molecular Targets

teriparatide acts on 1 molecular target:

PTH1Rparathyroid hormone 1 receptor (PTHR, EKNS)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

teriparatide is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Musculoskeletal and connective tissue disordersOsteoporosis✓ Approved

Related Research Articles

PubMedInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026-07-17

Pregnancy- and lactation-associated osteoporosis: A position statement of the IAPM, IOF, ECTS, ESCEO, IMS, and EMAS.

Hadji Peyman P, Athanasiadis Apostolos A, Brandi Maria-Luisa ML, Chakhtoura Marlene M et al.

Pregnancy- and lactation-associated osteoporosis (PLO) is a syndrome characterized by fragility fractures (most commonly vertebral, often multiple) occurring in late pregnancy or the early postpartum period. This position statement summarizes the current knowledge of PLO, and the recommended procedure for assessment, diagnosis and treatment based on a review of published evidence. As PLO is a rare condition, controlled, comparative clinical studies are limited. Individual studies were reviewed, focusing on design, size, follow-up, evaluation of safety, and factors that impact PLO outcomes. Diagnosis of PLO should include a detailed clinical examination, a review of medical and treatment history, and laboratory tests to rule out secondary osteoporosis. Imaging techniques can be used to inform the appropriate treatment pathway, which will depend on whether the patient is antepartum or postpartum. Management of PLO and fractures includes calcium/vitamin D intake/supplementation, considering stopping breastfeeding, and analgesia, if necessary. Treatment with bone-specific agents should be evaluated on an individual basis to reduce subsequent fracture risk, noting that their use in PLO patients is off label. If pharmacological treatments are used, they must be given alongside effective contraceptive measures. Bisphosphonates can pass the placental barrier and are detectable in bone for years, so adverse effects on future pregnancies, although not yet reported, cannot be excluded. Preferred treatment options are teriparatide/abaloparatide or romosozumab. Second-choice treatments are denosumab followed by bisphosphonates or bisphosphonates alone. This position statement includes a pragmatic approach for identifying women with PLO and suggests developing an individualized treatment plan that might include pharmaceutical intervention.

PMID 42464584
Read full article →
PubMedJBJS case connector2026-07-16

The Effect of Teriparatide in a Brown Tumor Patient With Pathological Hip Fracture: A Case Report and Literature Review.

Abdel-Hadi Dalia D, Al Lawati Ali A, Al Farkani Ahmed A, Al Badaai Yahya Y et al.

A 32-year-old man with end-stage renal disease (ESRD) from anti-neutrophil cytoplasmic antibody-associated vasculitis and tertiary hyperparathyroidism, presented with progressive right hip pain. A giant cell-rich lesion biopsy confirmed Brown tumor. Despite cinacalcet and vitamin D, hyperparathyroidism persisted, necessitating parathyroidectomy complicated by hungry bone syndrome and a pathological right hip fracture. Surgical fixation and prosthetic replacement were deferred due to high risk factors such as, ESRD and fracture pattern, as well as potential for postoperative implant failure and infection. Teriparatide was initiated to promote bone remodeling, leading to pain relief and radiographic improvement. To our knowledge, this is the first reported long-bone Brown tumor successfully treated with teriparatide.

PMID 42462050
Read full article →
PubMedJAMA2026-07-16

Hip Fractures: A Review.

Johannesdottir Fjola F, Roberts Jimmie E JE, Kiel Douglas P DP, Tsai Joy N JN

More than 14.2 million people worldwide and 280 000 in the US experience a hip fracture each year. The median 1-year mortality rate after a hip fracture is 22% and approximately 42% to 71% of patients regain their prefracture level of basic activities of daily living within 6 months. Hip fractures are classified as intracapsular or extracapsular and most commonly occur after a fall. Intracapsular hip fractures include femoral neck (34%) and femoral head (rare). Extracapsular fractures consist of intertrochanteric (48%) and subtrochanteric fractures (5.8%). In the US, between 2008 and 2017, hip fractures were associated with 1-year mortality rates of 26.9% among men and 18.5% among women. Older age is a major risk factor for hip fracture, with a hazard ratio of 1.35 (95% CI, 1.25-1.47) per 5-year increase in age. Women have higher incidence of hip fractures than men due to accelerated bone loss after menopause and higher incidence of falls. Other risk factors for hip fractures include low bone mineral density (bone density of 1 SD or below that of healthy young adults measured by dual-energy x-ray absorptiometry), prior fracture, and factors contributing to falls, such as weak muscles, poor visual acuity, and smoking. Surgery for hip fracture typically consists of hip joint replacement or hip joint stabilization, using embedded hardware (open reduction and internal fixation). Patients with hip fracture benefit from physical therapy and fall reduction strategies, such as muscle-strengthening exercises and modifying medications associated with increased fall risk, such as antidepressants, and should be treated with antiresorptive medications, such as bisphosphonates (alendronate, zoledronic acid) or denosumab to prevent subsequent fracture. To prevent a hip fracture, patients with vertebral osteoporosis at the spine may require anabolic therapy, such as teriparatide, abaloparatide, or romosozumab, before starting an antiresorptive. Hip fractures may lead to mobility limitations; declines in physical, emotional, and social functioning; and reduced health-related quality of life. Hip fractures are common among older people and are associated with a 1-year mortality rate of 22% and with reduced mobility and quality of life. Surgical repair for hip fracture typically consists of joint replacement or open reduction and internal fixation. Hip fracture treatment also includes physical therapy, fall reduction strategies, and medications to protect against fracture, such as bisphosphonates; denosumab; or anabolic drugs, such as parathyroid hormone analogues or romosozumab.

PMID 42461643
Read full article →
PubMedOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026-07-15

Influence of bisphosphonate pretreatment on bone mineral density gains and fracture outcomes with teriparatide: A systematic review and meta-analysis.

Pal Rimesh R, Banerjee Mainak M, Yadav Urmila U, Patra Shinjan S et al.

Teriparatide is a potent anabolic therapy for osteoporosis and is frequently prescribed after prior bisphosphonate (BP) treatment in routine clinical practice. Whether such pretreatment alters teriparatide efficacy, particularly with respect to fracture outcomes, remains uncertain. We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines (PROSPERO: CRD420251234859). PubMed/MEDLINE, Embase, and Scopus were searched from inception to November 30, 2025. Randomized trials, non-randomized trials, observational studies, and post hoc or subgroup analyses comparing teriparatide efficacy in BP-pretreated versus BP-naïve individuals were included. Outcomes included percentage change in areal bone mineral density (BMD) at the lumbar spine, hip, and femoral neck, and incident fractures. Random-effects models with Hartung-Knapp adjustment were used. Fifteen studies involving 8,763 BP-pretreated and 7,071 BP-naïve individuals were analysed. Prior BP exposure was associated with a significantly smaller increase in lumbar spine BMD following teriparatide (mean difference [MD] -2.21%; 95% CI -4.17,-0.25; p = 0.027). No significant differences were observed at the hip (MD -0.88%; 95% CI -1.98,0.19; p = 0.108) or femoral neck (MD -0.52%; 95% CI -1.36,0.33; p = 0.230). Pooling of absolute fracture events suggested a higher fracture risk in BP-pretreated patients (OR 1.43; 95% CI 1.09,1.88; p = 0.009), whereas pooled adjusted hazard ratios did not show a statistically significant difference (HR 1.35; 95% CI 0.99,1.83; p = 0.055). Prior bisphosphonate exposure is associated with modest, site-specific attenuation of lumbar spine BMD gains with teriparatide, without significant effects at non-spinal sites. Available fracture data remain inconclusive and adjusted analyses, albeit based on only two studies, do not indicate a clear attenuation of fracture protection. Prior bisphosphonate exposure may attenuate teriparatide response, but its clinical relevance is unclear. In this meta-analysis, lumbar spine BMD gains were modestly reduced, while hip/femoral neck BMD and adjusted fracture outcomes were not significantly affected. These findings support the continued use of teriparatide either before or after bisphosphonates when clinically indicated.

PMID 42455318
Read full article →
PubMedEndocrinology, diabetes & metabolism case reports2026-07-15

Osteoporosis associated with pregnancy and lactation (PLO): can REMS have a role in prevention and follow-up?

Al Refaie Antonella A, Mondillo Caterina C, Baldassini Leonardo L, Tarquini Roberto R et al.

Osteoporosis associated with pregnancy and lactation (PLO) is a debilitating premenopausal osteoporosis that occurs during the last trimester of pregnancy or breastfeeding. Its pathogenesis is complex and remains unclear, and there are currently no established guidelines. Case reports are valuable for clinicians in diagnosis, management, and treatment. We report a case of a young woman with multiple vertebral fractures who received a diagnosis of PLO. The patient was treated with vitamin D, teriparatide, and lifestyle modifications. We monitored the patient's bone mineral density using radiofrequency echographic multi-spectrometry (REMS) technology, a novel ultrasound tool for bone status evaluation. The ability to follow up young patients at risk of PLO using this safe, non-ionizing radiation tool could represent a significant advancement in the management of this condition.

PMID 42455974
Read full article →
PubMedUnfallchirurgie (Heidelberg, Germany)2026-07-14

[Adjunctive therapies in geriatric ankle fracture patients].

Stange Richard R, Kronenberg Daniel D

Ankle fractures are among the most common fragility fractures in older adults. Osteoporosis, age-related impairment of bone regeneration, and multimorbidity increase the risk of delayed union, nonunion, and postoperative complications. Besides anatomical reduction and stable fixation, adjunctive therapies aimed at enhancing biological fracture healing have gained growing interest. This review summarizes the pathophysiological aspects of fracture healing in elderly patients and evaluates current biological, pharmacological, and physical strategies to promote healing after geriatric ankle fractures. Osteoporosis is the major risk factor for impaired fracture healing, affecting both bone regeneration and implant stability. Comprehensive osteoporosis management forms the basis of adjunctive treatment. Antiresorptive therapies mainly reduce the risk of subsequent fragility fractures without significantly impairing fracture consolidation. Among osteoanabolic agents, teriparatide has shown promising effects on callus formation and fracture union. Growth factors such as bone morphogenetic proteins (BMPs) and platelet-derived growth factor (PDGF) possess osteoinductive properties but are limited to selected indications. Although platelet-rich plasma (PRP) is biologically attractive, current evidence does not support its routine use in geriatric ankle fractures. Cell-based therapies and biophysical stimulation techniques, including low-intensity pulsed ultrasound, may benefit selected high-risk patients but require further clinical validation. Early functional mobilization remains a key component of successful treatment. Enhancing fracture healing in geriatric ankle fractures requires a multimodal approach combining mechanical stability with biological augmentation.

PMID 42446566
Read full article →

+2850 more articles available with a free account

Sign up free to view all articles →

Ask about teriparatide